miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model
Elisa Callegari(University of Ferrara), Massimo Negrini(University of Ferrara), Paola Guerriero(University of Ferrara), Luciano Giacomelli(University of Padua), Simona Ultimo(University of Ferrara), Lucilla D’Abundo(University of Ferrara), Bahaeldin K. Elamin(University of Khartoum), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Barbara Zagatti(University of Ferrara), Luca M. Neri(University of Ferrara), Carolina Simioni(University of Ferrara), Laura Gramantieri(Second Military Medical University), Farzaneh Moshiri(University of Ferrara), Giuseppe Altavilla(Azienda Ospedaliera Universitaria Policlinico "G. Martino"), Marta Russo(European Institute of Oncology), Stella Blandamura(University of Padua), Cristian Bassi(University of Ferrara), Silvia Sabbioni(University of Ferrara), Alice Cani(University of Ferrara)
Cited by 100
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging
|Oncotarget|2018|522
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368